Prosecution Insights
Last updated: July 17, 2026
Application No. 18/290,558

Osteoconductive Implant Material with BMP-2 Delivery

Non-Final OA §112
Filed
Nov 14, 2023
Priority
May 14, 2021 — GB 2106973.7 +1 more
Examiner
BRUTUS, JOEL F
Art Unit
3797
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Locate Bio Limited
OA Round
1 (Non-Final)
73%
Grant Probability
Favorable
1-2
OA Rounds
9m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
941 granted / 1295 resolved
+2.7% vs TC avg
Strong +18% interview lift
Without
With
+17.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
36 currently pending
Career history
1344
Total Applications
across all art units

Statute-Specific Performance

§101
1.9%
-38.1% vs TC avg
§103
82.3%
+42.3% vs TC avg
§102
4.9%
-35.1% vs TC avg
§112
9.0%
-31.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1295 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-5, 7-8, 10, 12. 14-17 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 1, the phrase "optionally" renders the claim(s) indefinite because the claim(s) include(s) elements not actually disclosed (those encompassed by "or the like"), thereby rendering the scope of the claim(s) unascertainable. See MPEP § 2173.05(d). Claims 2-5, 7-8, 10, 12. 14-17 are rejected for the same reasons as set forth above. Allowable Subject Matter Claim 1 would be allowable if rewritten or amended to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action. The following is an examiner’s statement of reasons for allowance: No prior arts of record alone or in combination discloses the following: “(A) a plurality of pellets selected from calcium phosphate pellets and/or calcium phosphate-encapsulating pellets, wherein the calcium phosphate-encapsulating pellets comprise: 40-60% w/w PLGA having an L:G ratio ranging from 75:25 to 40-60% w/w calcium encapsulated within the PLGA; (B) a plurality of BMP-2 encapsulating pellets comprising 60-90% w/w PLGA having an L:G ratio ranging from 45:55 10-30% w/w 2-hydroxypropyl-β-cyclodextrin, 5-15% w/w poloxamer 407, and BMP-2, wherein the BMP-2 is encapsulated within the PLGA; and (C) a viscosity modifier optionally and optionally (D) an aqueous carrier. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled “Comments on Statement of Reasons for Allowance.” Prior arts Guelcher et al disclose putty may also refer to composites that have relatively high osteoconductive solid particulate content (e.g., >45 wt %-55 wt %), such as allograft or synthetic allograft. Putties may be molded to retain a particular shape [see 0060-061]. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOEL F BRUTUS whose telephone number is (571)270-3847. The examiner can normally be reached Mon-Sat, 11:00 AM to 7:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anne Kozak can be reached at 571-270-0552. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JOEL F BRUTUS/Primary Examiner, Art Unit 3797
Read full office action

Prosecution Timeline

Nov 14, 2023
Application Filed
Jun 17, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12678126
SAFETY ALERT BASED ON 4D INTRACARDIAC ECHO (ICE) CATHETER TRACKING
1y 8m to grant Granted Jul 14, 2026
Patent 12661499
SENSORS FOR CATHETER PUMPS
1y 11m to grant Granted Jun 23, 2026
Patent 12653480
METHOD AND APPARATUS FOR PERFORMING SINGLE GATING IN POSITRON EMISSION TOMOGRAPY SYTEMS
3y 0m to grant Granted Jun 16, 2026
Patent 12653496
INTRAVASCULAR IMAGING CATHETER
1y 6m to grant Granted Jun 16, 2026
Patent 12648745
SYSTEM AND METHOD FOR LOCAL THREE DIMENSIONAL VOLUME RECONSTRUCTION USING A STANDARD FLUOROSCOPE
2y 1m to grant Granted Jun 09, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
73%
Grant Probability
90%
With Interview (+17.7%)
3y 5m (~9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1295 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month